EPF’s feedback on the Implementing Act on HTA cooperation with EMA

The European Patients' Forum (EPF) welcomes the publication of the European Commission's draft Implementing Act on Health Technology Assessment (HTA) in cooperation with the European Medicines Agency (EMA).

We strongly support close interaction between regulators and HTA bodies to enable faster patient access to medicines. Although the EMA’s assessment is distinct from the HTA one at the EU level, the two processes are closely interlinked and affect the entire medicine lifecycle, including determining whether a medicine provides significant benefit.

Read our response to the European Commission's public consultation here.